STOCK TITAN

Astria Therapeutics Inc - ATXS STOCK NEWS

Welcome to our dedicated news page for Astria Therapeutics (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astria Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astria Therapeutics's position in the market.

Rhea-AI Summary
Astria Therapeutics, Inc. (NASDAQ:ATXS) appoints Dr. Sunil Agarwal, a seasoned biotechnology expert, to its Board of Directors. Dr. Agarwal brings over 20 years of experience in drug development and clinical expertise. His appointment aims to advance the company's programs, particularly STAR-0215, targeting hereditary angioedema.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
management
-
Rhea-AI Summary
Astria Therapeutics, Inc. (ATXS) granted stock options to purchase 9,000 shares of common stock under its 2022 Inducement Stock Incentive Plan. The options have an exercise price of $13.51, vesting over a four-year period, subject to the employee's continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
none
-
Rhea-AI Summary
Astria Therapeutics, Inc. (ATXS) announces positive proof-of-concept results for STAR-0215 in treating hereditary angioedema, showing a reduction of 90-96% in monthly attack rates. Phase 3 initiation planned for Q1 2025 with top-line results expected by 2026. Well-tolerated with no serious adverse events. Cash expected to fund operations until mid-2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
Rhea-AI Summary
Astria Therapeutics, Inc. (ATXS) granted stock options to purchase 40,000 shares of common stock under the 2022 Inducement Stock Incentive Plan. The options have an exercise price of $14.98 and will vest over a four-year period. This move aims to attract and retain key talent in the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.14%
Tags
none
-
Rhea-AI Summary
Astria Therapeutics, Inc. (ATXS) reported financial results for Q4 and full year 2023, highlighting progress in STAR-0215 for HAE and STAR-0310 for atopic dermatitis. They anticipate proof-of-concept data for STAR-0215 in Q1 2024 and an IND submission for STAR-0310 by year-end 2024. Astria closed an offering, raising $125.0 million, with a cash position of $246.5 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
-
Rhea-AI Summary
Astria Therapeutics, Inc. (ATXS) to present final Phase 1a healthy subject data for STAR-0215 at AAAAI Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
conferences
Rhea-AI Summary
Astria Therapeutics, Inc. (ATXS) CEO, Dr. Jill C. Milne, to participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The webcast will be available on February 13th at 9:20am ET, with a replay accessible for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
conferences
-
Rhea-AI Summary
Astria Therapeutics, Inc. (Nasdaq:ATXS) granted stock options to purchase 21,000 shares of common stock under the 2022 Inducement Stock Incentive Plan. The options have an exercise price of $13.56 and will vest over a four-year period. This grant was made to two employees entering into employment with Astria, as per Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
-
Rhea-AI Summary
Astria Therapeutics, Inc. (ATXS) has announced the pricing of an underwritten offering of 10,340,000 shares of its common stock at a price of $12.09 per share, with expected gross proceeds of approximately $125 million. The offering is expected to close soon, and all securities are being offered by Astria.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.62%
Tags
none
Rhea-AI Summary
Astria Therapeutics, Inc. (Nasdaq:ATXS) granted 52,000 stock options under the 2022 Inducement Stock Incentive Plan to two new employees on December 1, 2023. The options have an exercise price of $4.75 and will vest over a four-year period, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
none
Astria Therapeutics Inc

Nasdaq:ATXS

ATXS Rankings

ATXS Stock Data

609.42M
36.14M
0.49%
88.01%
9.22%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston